Advances in Topical Botulinum Therapy.
Journal
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
ISSN: 1524-4725
Titre abrégé: Dermatol Surg
Pays: United States
ID NLM: 9504371
Informations de publication
Date de publication:
01 Sep 2024
01 Sep 2024
Historique:
medline:
29
8
2024
pubmed:
29
8
2024
entrez:
28
8
2024
Statut:
ppublish
Résumé
A successfully developed topical botulinum toxin product would overcome the disadvantages of injectable administration commonly seen with all available botulinum products, including the potential pain, bleeding, and bruising associated with injection. Identify the disadvantages of injectable administration of botulinum products and advantages of topical administration. Identify previous attempts to develop topical products and review the only topical product candidate (ET-01, abbreviated EMX) under clinical development. A literature review regarding injectable botulinum products and topical botulinum product candidates and an analysis of data regarding EMX development were performed. Multiple disadvantages of injectable administration and advantages of topical administration of botulinum toxin were identified. If available, topical botulinum products are expected to expand the clinical use of botulinum toxin. Several previous attempts to develop topical products were identified. EMX has been studied for lateral canthal line treatment in multiple controlled phase 2 clinical trials including over 700 subjects. EMX has demonstrated statistically significant positive results. The development of a topical botulinum toxin is appealing because it overcomes multiple disadvantages observed with injectable administration and would likely result in increased clinical use of botulinum toxin. The development of EMX shows promise and merits further study.
Sections du résumé
BACKGROUND
BACKGROUND
A successfully developed topical botulinum toxin product would overcome the disadvantages of injectable administration commonly seen with all available botulinum products, including the potential pain, bleeding, and bruising associated with injection.
OBJECTIVE
OBJECTIVE
Identify the disadvantages of injectable administration of botulinum products and advantages of topical administration. Identify previous attempts to develop topical products and review the only topical product candidate (ET-01, abbreviated EMX) under clinical development.
MATERIALS AND METHODS
METHODS
A literature review regarding injectable botulinum products and topical botulinum product candidates and an analysis of data regarding EMX development were performed.
RESULTS
RESULTS
Multiple disadvantages of injectable administration and advantages of topical administration of botulinum toxin were identified. If available, topical botulinum products are expected to expand the clinical use of botulinum toxin. Several previous attempts to develop topical products were identified. EMX has been studied for lateral canthal line treatment in multiple controlled phase 2 clinical trials including over 700 subjects. EMX has demonstrated statistically significant positive results.
CONCLUSION
CONCLUSIONS
The development of a topical botulinum toxin is appealing because it overcomes multiple disadvantages observed with injectable administration and would likely result in increased clinical use of botulinum toxin. The development of EMX shows promise and merits further study.
Identifiants
pubmed: 39196836
doi: 10.1097/DSS.0000000000004344
pii: 00042728-202409001-00014
doi:
Substances chimiques
Botulinum Toxins, Type A
EC 3.4.24.69
Neuromuscular Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
S64-S69Informations de copyright
Copyright © 2024 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.
Références
Carruthers A, Carruthers J, Hardas B, Kaur M, et al. A validated grading scale for Crow's feet. Dermatol Surg 2008;34:S173–8.
Cavallini M, Papagni M, Gazzola R. An objective method to assess the improvements of skin texture roughness after botulinum toxin type a treatment of crow’s feet. Skin Res Technol. 2019;25:54–9.
Donofrio L, Carruthers A, Hardas B, Murphy D, et al. Development and validation of a photonumeric scale for evaluation of facial skin texture. Dermatol Surg 2016;42:S219–26.
Allergan, Inc. Medical Aesthetics Analyst Day; 2018. Available from: https://news.abbvie.com/2018-09-14-Allergan-Highlights-Key-Growth-Drivers-for-Medical-Aesthetics. Accessed March 9, 2024.
Leclerc O, Peters N, Scaglione A, Waring J. From Extreme to Mainstream: The Future of Aesthetic Injectables; 2021. Available from https://www.mckinsey.com/industries/life-sciences/our-insights/from-extreme-to-mainstream-the-future-of-aesthetics-injectables. Accessed March 9, 2024.
Fabi S, Alexiades M, Chatrath V, Colucci L, et al. Facial aesthetic priorities and concerns: a physician and patient perception global survey. Aesthet Surg J 2022;42:NP218–29.
Anterios, Inc. Anterios Wrinkle Survey; 2015. Available from: https://www.sec.gov/Archives/edgar/data/1390085/000091205715000031/filename1.htm. Accessed March 4, 2024.
Doolittle J, Walker P, Mills T, Thurston J. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res 2016;308:743–9.
Anterios, Inc. Anterios Hyperhidrosis Survey; 2015. Available from: https://www.sec.gov/Archives/edgar/data/1390085/000091205715000031/filename1.htm. Accessed March 4, 2024.
Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 2000;9:165–9.
Benson HAE, Grice JE, Mohammed Y, Namjoshi S, et al. Topical and transdermal drug delivery: from simple potions to smart technologies. Curr Drug Deliv 2019;16:444–60.
Hardas B, Brin MF. Topical botulinum type A. In: Carruthers A, Carruthers J, Dover JS, Alam M, editors. Botulinum Toxin (4th ed). Edinburgh: Elsevier; 2018; pp. 81–4.
National Library of Medicine. 2024. Available from: https://www.clinicaltrials.gov/search?term=topica%20botulinum. Accessed March 4, 2024.
Collins A, Nasir A. Topical botulinum toxin. J Clin Aesthet Dermatol 2010;3:35–9.
Waugh JM, Glogau RG. Topical daxibotulinumtoxinA (RT-001). In: Carruthers A, Carruthers J, Dover JS, Alam M, editors. Botulinum Toxin (4th ed). Edinburgh: Elsevier; 2018; pp. 77–80.
Edelson J, Nicolosi R. US Patent 8,318,181: Botulinum Nanoemulsions; 2012. Available from https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8318181. Accessed March 9, 2024.
Edelson J, Nicolosi R. US Patent 9,486,408: Botulinum Nanoemulsions; 2016. Available from https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9486408. Accessed March 9, 2024.
Edelson J, Nicolosi R. US Patent 10,532,019: Botulinum Nanoemulsions; 2020. Available from https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10532019. Accessed March 9, 2024.
Edelson J, Nicolosi R. US Patent 10,576,034: Botulinum Nanoemulsions; 2020. Available from https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10576034. Accessed March 9, 2024.
Zhang S, Qiu Y, Gaoet Y. Enhanced delivery of hydrophilic peptides in vitro by transdermal microneedle pretreatment. Acta Pharm Sin B 2014;4:100–4.
Edelson J. US Patent 11,311,496: Transdermal Delivery of Large Agents; 2022. Available from https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11311496. Accessed March 9, 2024.
Nair PA, Tandel J. Microneedling: a means of collagen induction therapy. J Dermatol Dermatol Surg 2021;25:49–53.